Cargando…

Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability

 Presuming that Alzheimer’s disease (AD) might represent an antagonistic pleiotropic phenomenon derived from the evolvability of multiple amyloidogenic proteins, targeting such proteins simultaneously could enhance therapeutic efficacy. Furthermore, considering that amyloid-β (Aβ) immunotherapies du...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Gilbert, Choo, Pei Chen, Waragai, Masaaki, Inoue, Satoshi, Masliah, Eliezer, Hashimoto, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108623/
https://www.ncbi.nlm.nih.gov/pubmed/35591950
http://dx.doi.org/10.3233/ADR-210021
_version_ 1784708746846404608
author Ho, Gilbert
Choo, Pei Chen
Waragai, Masaaki
Inoue, Satoshi
Masliah, Eliezer
Hashimoto, Makoto
author_facet Ho, Gilbert
Choo, Pei Chen
Waragai, Masaaki
Inoue, Satoshi
Masliah, Eliezer
Hashimoto, Makoto
author_sort Ho, Gilbert
collection PubMed
description  Presuming that Alzheimer’s disease (AD) might represent an antagonistic pleiotropic phenomenon derived from the evolvability of multiple amyloidogenic proteins, targeting such proteins simultaneously could enhance therapeutic efficacy. Furthermore, considering that amyloid-β (Aβ) immunotherapies during reproductive life stage might adversely decrease Aβ evolvability in an offspring’s brain, the disease-modifying Aβ immunotherapies should be limited to post-reproductive time in lifespan. Thus, current Aβ immunotherapy strategies should be revised accordingly. Given that the “adiponectin paradox” might underlie both amyloidosis and cognitive dysfunction in aging brain, blocking activin signaling situated downstream of the adiponectin paradox might be an alternative strategy to prevent AD.
format Online
Article
Text
id pubmed-9108623
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-91086232022-05-18 Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability Ho, Gilbert Choo, Pei Chen Waragai, Masaaki Inoue, Satoshi Masliah, Eliezer Hashimoto, Makoto J Alzheimers Dis Rep Commentary  Presuming that Alzheimer’s disease (AD) might represent an antagonistic pleiotropic phenomenon derived from the evolvability of multiple amyloidogenic proteins, targeting such proteins simultaneously could enhance therapeutic efficacy. Furthermore, considering that amyloid-β (Aβ) immunotherapies during reproductive life stage might adversely decrease Aβ evolvability in an offspring’s brain, the disease-modifying Aβ immunotherapies should be limited to post-reproductive time in lifespan. Thus, current Aβ immunotherapy strategies should be revised accordingly. Given that the “adiponectin paradox” might underlie both amyloidosis and cognitive dysfunction in aging brain, blocking activin signaling situated downstream of the adiponectin paradox might be an alternative strategy to prevent AD. IOS Press 2022-04-27 /pmc/articles/PMC9108623/ /pubmed/35591950 http://dx.doi.org/10.3233/ADR-210021 Text en © 2022 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Ho, Gilbert
Choo, Pei Chen
Waragai, Masaaki
Inoue, Satoshi
Masliah, Eliezer
Hashimoto, Makoto
Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
title Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
title_full Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
title_fullStr Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
title_full_unstemmed Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
title_short Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
title_sort reconsideration of alzheimer’s disease therapy from a viewpoint of amyloidogenic evolvability
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108623/
https://www.ncbi.nlm.nih.gov/pubmed/35591950
http://dx.doi.org/10.3233/ADR-210021
work_keys_str_mv AT hogilbert reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability
AT choopeichen reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability
AT waragaimasaaki reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability
AT inouesatoshi reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability
AT masliaheliezer reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability
AT hashimotomakoto reconsiderationofalzheimersdiseasetherapyfromaviewpointofamyloidogenicevolvability